Abstract:Activation of co-stimulatory pathways in cytotoxic T lymphocytes expressing chimeric antigen receptors (CARs) have proven to boost effector activity, tumor rejection and long-term T cell persistence. When using antigen-specific T cell receptors (TCR) instead of CARs, the lack of co-stimulatory signals hampers robust antitumoral response, hence limiting clinical efficacy. In solid tumors, tumor stroma poses an additional hurdle through hindrance of infiltration and active inhibition. Our project aimed at generating chimeric co-stimulatory switch proteins (CSP) consisting of intracellular co-stimulatory domains (ICD) fused to extracellular protein domains (ECD) for which ligands are expressed in solid tumors. The ECD of CD40L was selected for combination with the ICD from the CD28 protein. With this approach, it was expected to not only provide co-stimulation and strengthen the TCR signaling, but also, through the CD40L ECD, facilitate the activation of tumor-resident antigen-presenting cells (APCs), modulate activation of tumor endothelium and induce TCR-MHC independent apoptotic effect on tumor cells. Since CD28 and CD40L belong to different classes of transmembrane proteins (type I and type II, respectively), creating a chimeric protein presented a structural and functional challenge. We present solutions to this challenge describing different CSP formats that were successfully expressed in human T cells along with an antigen-specific TCR. The level of surface expression of the CSPs depended on their distinct design and the state of T cell activation. In particular, CSPs were upregulated by TCR stimulation and downregulated following interaction with CD40 on target cells. Ligation of the CSP in the context of TCR-stimulation modulated intracellular signaling cascades and led to improved TCR-induced cytokine secretion and cytotoxicity. Moreover, the CD40L ECD exhibited activity as evidenced by effective maturation and activation of B cells and DCs. CD40L:CD28 CSPs are a new type of switch proteins designed to exert dual beneficial antitumor effect by acting directly on the gene-modified T cells and simultaneously on tumor cells and tumor-supporting cells of the TME. The observed effects suggest that they constitute a promising tool to be included in the engineering process of T cells to endow them with complementary features for improved performance in the tumor milieu.

Enhanced interaction between SEC2 mutant and TCR Vβ induces MHC II-independent activation of T cells via PKCθ/NF-κB and IL-2R/STAT5 signaling pathways

Up-regulation of Granzyme B and Perforin by Staphylococcal Enterotoxin C2 Mutant Induces Enhanced Cytotoxicity in Hepa1–6 Cells

Staphylococcal Enterotoxin C2 Mutant-Directed Fatty Acid and Mitochondrial Energy Metabolic Programs Regulate CD8+ T Cell Activation.

Soluble Expression of Fc-Fused T Cell Receptors Allows Yielding Novel Bispecific T Cell Engagers

Granzyme B and Perforin Produced by SEC2 Mutant-Activated Human CD4+ T Cells and CD8+ T Cells Induce Apoptosis of K562 Leukemic Cells by the Mitochondrial Apoptotic Pathway.

Enhancement of antitumor response of staphylococcal enterotoxin C2 mutant 2M-118 by promoting cell-mediated antitumor immunity

Conditional Deletion Of Shp2 Tyrosine Phosphatase In Thymocytes Suppresses Both Pre-Tcr And Tcr Signals

Cis Interactions Between CD2 and Its Ligands on T Cells Are Required for T Cell Activation

STAP-2 Is a Novel Positive Regulator of TCR-Proximal Signals

Enhancing the Antitumor Immunity of T Cells by Engineering the Lipid-Regulatory Site of the TCR/CD3 Complex

Enhancing the Antitumor Response of CD8+ T Cells by 4-1BB (CD137) Co-Stimulation with Distinct Inactivation of the Type 2 Adenosine Receptors

Stimulation of ectopically expressed muscarinic receptors induces IFN-γ but suppresses IL-2 production by inhibiting activation of pAKT pathways in primary T cells

TSC2 S1365A mutation potently regulates CD8+ T cell function and differentiation and improves adoptive cellular cancer therapy

Suppression of Tumorigenicity 2 (st2) Signaling is Required for Regulatory T Cell Control of Graft-Vs. Host Disease

SLP-76 interaction with PLC-γ1 fine-tunes TCR signal strength for appropriate thymocyte selection, T cell homeostasis, and Ag-specific T cell response

Up-Regulation of Cbl-B is Associated with Lsectin-Mediated Inhibition of Different Cd4(+) T-Cell Subsets

Effects of Dendritic Cells Induced by Superantigen Staphylococcal Enterotoxin B or Staphylococcal Enterotoxin C on T Lymphocytes

Isolation of a structural mechanism for uncoupling T cell receptor signaling from peptide-MHC binding

A trispecific T cell engager CD19xCD3xCD28 induces potent tumor-directed T cell activation and antitumor activity by simultaneously engagement of TCR and a co-stimulatory receptor CD28

Double Strike Approach for Tumor Attack: Engineering T Cells Using a CD40L:CD28 Chimeric Co-Stimulatory Switch Protein for Enhanced Tumor Targeting in Adoptive Cell Therapy

Non-Stimulatory pMHC Enhance CD8 T Cell Effector Functions by Recruiting Coreceptor-Bound Lck